Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.43 |
| ▸ | ROR1 | Q01973 | 3/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 6/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207631 | 0.80 | MKNK1 (0.44) | ABL1ROR1DDR1CSF1RDYRK1A | |
| SCHEMBL16201020 | 0.79 | ABL1 (0.39) | ABL1DDR1DDR2 | |
| SCHEMBL16201026 | 0.78 | ABL1 (0.53) | ABL1ROR1CSF1R | |
| SCHEMBL17471694 | 0.78 | ABL1 (0.53) | ABL1ROR1CSF1R | |
| SCHEMBL17471695 | 0.77 | ABL1 (0.53) | ABL1ROR1CSF1R | |
| SCHEMBL29890013 | 0.73 | MKNK1 (0.41) | ABL1ROR1DDR1DDR2CSF1R | |
| SCHEMBL23800981 | 0.73 | MKNK1 (0.38) | ABL1ROR1DDR1CSF1RDYRK1A | |
| SCHEMBL588504 | 0.71 | MKNK1 (0.44) | ABL1ROR1DDR1CSF1RDYRK1A | |
| SCHEMBL22369939 | 0.70 | MKNK1 (0.46) | ABL1ROR1DDR1CSF1RDYRK1A | |
| SCHEMBL24491379 | 0.69 | CSF1R (0.49) | ABL1ROR1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725452-B2 | Substituted indoles and pyrroles as RIP kinase inhibitors | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323489-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | ABL1 1547/4885ROR1 1517/4885DDR1 2020/4885 |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | ABL1 1547/4885ROR1 1517/4885DDR1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.